Knome appoints Martin Tolar as chief executive

Knome Inc., a Cambridge life sciences company specializing in human genome interpretation, today announced that it has appointed Martin Tolar, M.D., as its chief executive.

Knome supports researchers with the informatics and software tools used to investigate the genetic basis of human disease and drug response.


Before joining Knome, Tolar was chief executive of Normoxys Inc., where he helped build a management team, secure venture financings, and advance the company’s novel cancer therapeutics from a research project into clinical development, Knome said in a press release.

Jorge Conde, Knome’s founding CEO, will become chief strategy officer and continue to serve on its board of directors, Knome said; in his new role, he will lead the development of Knome’s genome interpretation software and services.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of